Companies › SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
3 active drug programs in 14 registered trials: 7 Phase 1, 6 Phase 2, 1 Phase 4; Oncology, Gastroenterology, Other; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Nirogacestat Gamma-secretase inhibitor | APH1A, PSENEN, APH1B, PSEN1, NCSTN | Phase 4 | Desmoid Tumor | May 2027 |
| Mirdametinib (PD-0325901) Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 2 | Plexiform Neurofibroma; Healthy; Slow-Flow Vascular Malformation; Advanced Unresectable Melanoma … | Dec 2028 |
| SW-682 Hippo pathway inhibitor | – | Phase 1 | Advanced Solid Tumor | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06997276 | Mirdametinib (PD-0325901) | Phase 1 | Healthy | Gastroenterology | Oct 2026 |
| NCT05983159 | Mirdametinib (PD-0325901) | Phase 2 | Slow-Flow Vascular Malformation | Other | Jan 2027 |
| NCT06251310 | SW-682 | Phase 1 | Advanced Solid Tumor | Oncology | Jan 2027 |
| NCT07170644 | Nirogacestat | Phase 2 | Desmoid Tumor | Oncology | May 2027 |
| NCT07237100 | Mirdametinib (PD-0325901) | Phase 2 | Advanced Unresectable Melanoma | Oncology | Oct 2027 |
| NCT05937906 | Mirdametinib (PD-0325901) | Phase 1 | Non-Small Cell Lung Cancer | Oncology | Jul 2028 |
| NCT06843967 | Mirdametinib (PD-0325901) | Phase 1 | Well Differentiated Liposarcoma | Oncology | Aug 2028 |
| NCT03962543 | Mirdametinib (PD-0325901) | Phase 2 | Plexiform Neurofibroma | Oncology | Dec 2028 |
| NCT07539441 | Mirdametinib (PD-0325901) | Phase 1 | Central Nervous System Tumors | Oncology | Oct 2029 |
| NCT07061951 | Mirdametinib (PD-0325901) | Phase 2 | Recurrent Chronic Lymphocytic Leukemia | Oncology | Feb 2030 |
| NCT06153173 | Mirdametinib (PD-0325901) | Phase 2 | Langerhans Cell Histiocytosis (LCH) | Oncology | Mar 2030 |
| NCT06666348 | Mirdametinib (PD-0325901) | Phase 1 | Pediatric Low-grade Glioma | Oncology | Apr 2030 |
| NCT07176689 | Nirogacestat | Phase 4 | Desmoid Tumor | Oncology | Feb 2031 |
| NCT04923126 | Mirdametinib (PD-0325901) | Phase 1 | Low-Grade Glioma | Oncology | Jun 2031 |
Roche GSK AstraZeneca Pierre Fabre Medicament Shanghai Kechow Pharma Pasithea Therapeutics Novartis Merck KGaA Verastem Pfizer
Shanghai Kechow Pharma Hinova Pharmaceuticals Xuanzhu Biopharmaceutical Shanghai Fosun Pharmaceutical Industrial Development Stemline Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.